FDA Advertising Letters, In Brief
Executive Summary
Cialis web promotions: A Jan. 3 letter from FDA Division of Drug Marketing, Advertising & Communications objects to websites promoting the safety and efficacy of Lilly/Icos' unapproved erectile dysfunction product Cialis (tadalafil), including statements that Cialis enables "a man with ED to engage in intercourse within a 24-hour window" and "regain spontaneity;" that data suggests "dosing for Cialis should be simple and uncomplicated" and that "Cialis was well-tolerated, with generally mild-to-moderate side effects that diminished in frequency with continued treatment." Lilly said the companies will remove the identified items...
You may also be interested in...
Roche Xeloda “Reminder” Ad Cited By FDA For Reference to Oral Delivery
Roche's use of the phrase "oral chemotherapy" in a direct-to-consumer "reminder" ad makes the ad product-specific for Xeloda, FDA said in a Jan. 9 letter
Roche Xeloda “Reminder” Ad Cited By FDA For Reference to Oral Delivery
Roche's use of the phrase "oral chemotherapy" in a direct-to-consumer "reminder" ad makes the ad product-specific for Xeloda, FDA said in a Jan. 9 letter
Pharmacia Genotropin (correction)
Genotropin is approved for the long-term treatment of growth failure in pediatric patients who were born small for gestational age and fail to manifest catch-up growth by age two. "The Pink Sheet" incorrectly stated the indication in an item about a letter from the FDA ad division regarding a Pharmacia mailing to doctors (1"The Pink Sheet" Jan. 21, p. 37)...